The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Aurora Tele-Oncology Platform; HUTCHMED; Insighta Holdings Limited
Stock and Other Ownership Interests - Alentis Therapeutics; AstraZeneca; Aurora Tele-Oncology Platform; Biolidics; D3 Bio; HUTCHMED; Lunit; Prenetics
Honoraria - Abbvie; ACEA Pharmaceutical Research; Adagene; Alpha Biopharma; Amgen; Amoy Diagnostics; AnHeart Therapeutics; AstraZeneca; AVEO; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Daz Group; Eisai; Fishawack Facilitate; Gilead Sciences; GLG’s Healthcare; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Illumina; Incyte; Inivata; InMed; IQVIA; Janssen; Jiahui Holdings Co; Lakeshore Biotechnology; Lilly; Lucence; Lucence; MD Health Brazil,; Medscape; Merck; Merck Sharp & Dohme; MiRXES; Novartis; Novocure; Omega Therapeutics; Origimed; PeerVoice; Permanyer Publications; Pfizer; Physicans' Education Resource; Prenetics; Prime Oncology; Qiming Development (HK) Ltd.; Regeneron; Research to Practice; Roche; Sanofi Aventis GmbH; SFJ Pharmaceutical Ltd; Shanghai BeBirds Translation & Consulting; Shanghai Promedican Pharmaceuticals Co., Ltd; Simcere of America Inc.; Summit Therapeutics Sub, Inc.; Suzhou Liangyihui Network Technology; Synergy Research; Taiho Pharmaceutical; Takeda; Tigermed; touchIME; Vertex; Virtus Medical Group; Xencor; Yuhan
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Adagene; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; Bayer HealthCare Pharmacuticals; BeiGene; BerGenBio; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bowtie Life Insurance Company; Bridgebio; Bristol-Myers Squibb; C4 Therapeutics; Cirina; Covidien/Medtronic; Covidien/Medtronic; CStone Pharmaceuticals; Curio Science; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Fishawack Facilitate; G1 Therapeutics; geneDecode; Genentech; Gilead Sciences; Gritstone Bio; Guardant Health; Hengrui Therapeutics; HUTCHMED; Ignyta; Imagene AI Ltd.; Incyte; Inivata; IQvia; Janssen; Lakeshore Biotechnology; Lilly; Loxo; Lucence; Lunit; Medtronic; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; MiRXES; Novartis; Omega Therapeutics; OrigiMed; OSE Immunotherapeutics; Pfizer; Prenetics; PrIME Oncology; Puma Biotechnology; Qiming Development (HK) Ltd.; Regeneron; Roche; SFJ Pharmaceuticals Group; Simcere; Summit Therapeutics; Synergy Research; Takeda; Tigermed; Vertex; Virtus Medical Group; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Abbvie; Astrazeneca; Daiichi Sankyo; Liangyihui; MiRXES; Novartis; Pfizer; Pfizer; Roche; Zai Lab
 
Helena Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Bristol-Myers Squibb/Roche; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Orion Clinical; Taiho Oncology; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Sun Min Lim
Honoraria - Boehringer Ingelheim; Takeda; Yuhan
Research Funding - Janssen Research & Development
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; IPSEN; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Novocure; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Silvia Novello
Honoraria - Abbvie; AstraZeneca; BeiGene; BMS GmbH & Co. KG; Boehringer Ingelheim; Lilly; MSD; Pfizer; PharmaMar; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Lilly
Travel, Accommodations, Expenses - Sanofi
 
Christophe Dooms
Consulting or Advisory Role - MSD Oncology (Inst)
Travel, Accommodations, Expenses - MSD (Inst)
 
Jong-Mu Sun
No Relationships to Disclose
 
Steven Kao
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Research Funding - AstraZeneca/Daiichi Sankyo (Inst)
Expert Testimony - AstraZeneca/Daiichi Sankyo; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; MSD; Pfizer; Roche; Takeda
(OPTIONAL) Uncompensated Relationships - AstraZeneca/Daiichi Sankyo; Nuvalent, Inc.
 
Pasi Jänne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Blueprint Medicines; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Puma Biotechnology (Inst); Revolution Medicines (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
Expert Testimony - AstraZeneca
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline K.K.; IO Biotech; IO Biotech; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
(OPTIONAL) Uncompensated Relationships - “Medical writing assistance for this abstract was provided by Bena Lim, PhD, CMPP, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst); “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst)
 
Conor Steuer
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Caris Life Sciences; Daiichi Sankyo/Lilly; Lilly; Mirati Therapeutics; Novocure; Sanofi/Regeneron; Takeda
Research Funding - Daiichi Sankyo; Infinity Pharmaceuticals; Seagen; Vaccinex
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Xiaofang Li
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Ronan Fougeray
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Ragini Kudchadkar
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Jianyu Wu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Stephen Esker
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Antonio Passaro
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - AstraZeneca; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; MSD Oncology